A multicenter, open-label, non-inferiority, randomized controlled trial comparing mechanochemical endovenous ablation using Flebogrif with endovenous laser ablation in the treatment of primary great saphenous vein incompetence
Phase 4
Recruiting
- Conditions
- 10057165<p>Great spahenous vein incompetence</p>GSV incompetence
- Registration Number
- NL-OMON25145
- Lead Sponsor
- oordwest Ziekenhuisgroep
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 320
Inclusion Criteria
|
- Leeftijd 18-80 jaar |
Exclusion Criteria
|
- C6 varices |
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Flebogrif's mechanochemical ablation in treating GSV incompetence?
How does mechanochemical endovenous ablation compare to endovenous laser ablation in GSV incompetence management?
Are there specific biomarkers that predict optimal patient response to Flebogrif or EVLA treatments for GSV incompetence?
What are the known adverse events associated with Flebogrif versus endovenous laser ablation for primary GSV incompetence?
What are the current competitor technologies or drugs in the treatment of primary great saphenous vein incompetence?